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Background: Paraoxonase 1 (PON1) is a cardioprotective, HDL-associated glycoprotein enzyme with broad
substrate specificity. Our previous work found associations between dietary cholesterol and vitamin C with PON1
activity. The goal of this study was to determine the effect of specific dietary fatty acid (DFA) intake on PON1
activity.
Methods: 1,548 participants with paraoxonase activity measures completed the Harvard Standardized Food
Frequency Questionnaire to determine their daily nutrient intake over the past year. Eight saturated, 3
monounsaturated, and 6 polyunsaturated DFAs were measured by the questionnaire. To reduce the number of
observations tested, only specific fatty acids that were not highly correlated (r < 0.8) with other DFAs or that were
representative of other DFAs through high correlation within each respective group (saturated, monounsaturated,
or polyunsaturated) were retained for analysis. Six specific DFA intakes – myristic acid (14 carbon atoms, no double
bonds – 14:0), oleic acid (18:1), gadoleic acid (20:1), α-linolenic acid (18:3), arachidonic acid (20:4), and
eicosapentaenoic acid (20:5) – were carried forward to stepwise linear regression, which evaluated the effect of
each specific DFA on covariate-adjusted PON1 enzyme activity.
Results: Four of the 6 tested DFA intakes – myristic acid (p = 0.038), gadoleic acid (p = 6.68 × 10-7), arachidonic acid
(p = 0.0007), and eicosapentaenoic acid (p = 0.013) - were independently associated with covariate-adjusted PON1
enzyme activity. Myristic acid, a saturated fat, and gadoleic acid, a monounsaturated fat, were both positively
associated with PON1 activity. Both of the tested polyunsaturated fats, arachidonic acid and eicosapentaenoic
acid, were negatively associated with PON1 activity.
Conclusions: This study presents the largest cohort-based analysis of the relationship between dietary lipids and
PON1 enzyme activity. Further research is necessary to elucidate and understand the specific biological mechanisms,
whether direct or regulatory, through which DFAs affect PON1 activity.
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The beneficial effects of high-density lipoprotein (HDL)
on cardiovascular health have recently come under in-
creased scrutiny after both a large randomized clinical
trial [1] and separate Mendelian randomization study [2]
failed to show cardioprotective effects from raising HDL
cholesterol levels (HDL-C) alone. Instead, focus has
shifted to the atherosclerosis-related aspects of HDL
biology that are not reflected in HDL-C measurements,
such as paraoxonase 1 (PON1) activity.
PON1 is a glycoprotein enzyme with broad substrate
specificity [3], which is at least partly responsible for the
inhibitory and cardioprotective effects of HDL on lipid
peroxidation and its resulting atherogenesis [4]. In
addition to its cardioprotective effects, PON1 is protect-
ive against exposure to toxic organophosphorus (OP)
compounds [5]. The activity of PON1 is measured by its
catalytic efficiency for the hydrolysis of the substrates
paraoxon (POase), diazoxon (DZOase), and phenylace-
tate (AREase). Of these measurements of PON1 activity,
AREase is the most correlated with protein levels, as it is
not drastically affected by the PON1Q192R coding poly-
morphism [6,7].
Four well-known human polymorphisms affect PON1
activity: PON1C-108T (rs705379), PON1G-162A (rs705381),
PON1M55L (rs854560), and PON1Q192R (rs662). Of these,
PON1C-108T has the largest effect on PON1 AREase activity
due its promoter-altering properties [8-11], accounting for
approximately 15% of PON1 AREase variance [12]. The
PON1Q192R polymorphism [13] is the primary determinant
of toxic OP compound catalysis, accounting for over 65%
of PON1 POase activity [12]. Rare protein-truncating and
missense mutations in PON1 have been identified and asso-
ciated with PON1 activity [14,15].
Numerous environmental factors, including diet, have
been associated with differential PON1 activity [16,17].
However, while dietary cholesterol is associated with
PON1 activity in humans [18], the relationship between
dietary fatty acid (DFA) intake and PON1 remains un-
clear. For example, rats fed a diet rich in oleic acid, a
monounsaturated DFA (a fatty acid containing only a
single double bond in its carbon chain) found in olive
oil, had increased PON1 activity (+46%); however, when
the rats were switched to a diet high in polyunsaturated,
ω-3 and ω-6 DFAs, there was a significant decrease in
PON1 activity (−39%) [19]. Similarly, human studies
have found an increase in PON1 activity in 14 diabetic
patients after meals rich in thermally stressed olive oil,
with the effect greater in females than males [20]. Simi-
larly, oleic acid intake, as determined from a 12-hour
food recall survey, was found to be associated with in-
creased PON1 activity, although the effect was only sig-
nificant in subjects with the homozygous “RR” genotype
at PON1Q192R [21]. Finally, a decrease in PON1 activityin both healthy men and women when switching from a
diet rich in saturated fats to one composed primarily of
trans DFAs has been reported [22].
Research into the in vitro interaction of PON1 and DFAs
have similarly presented conflicting results. Negatively
charged lipids, including saturated, monounsaturated, and
polyunsaturated DFAs, have all been reported to inhibit
PON1 enzyme activity in vitro [23], with polyunsaturated
fatty acids having the largest inhibitory effect [24]. However,
monounsaturated fatty acids (and to a lesser extent, satu-
rated fats) have also been shown to protect PON1 from as-
corbate/copper-mediated oxidative inactivation [24,25].
Notably, polyunsaturated fats prevented this monounsatu-
rated DFA-dependent oxidative protective effect [24]. In
addition, monounsaturated fats have been reported to pre-
serve PON1 enzyme activity during lengthy in vitro incuba-
tion periods [24].
The Carotid Lesion Epidemiology and Risk (CLEAR)
cohort is a Seattle-based carotid artery disease (CAAD)
case–control cohort, comprised primarily of veterans,
collected to identify risk factors for CAAD, CAAD pro-
gression, and other atherosclerotic disease end-points.
Previous work in the CLEAR cohort has identified novel
dietary factors – vitamins C and E [26], cholesterol in-
take [18], and dietary iron in non-anemic subjects [18] –
which are associated with PON1 enzyme activity. The
majority of human studies examining the relationship
between DFAs and PON1 have been small (n < 100 sub-
jects), and the in vitro evidence conflicting. Thus, the
goal of the present study was to evaluate the effects of
specific DFA intakes on PON1 activity as measured by
AREase within this cohort of 1548 subjects, to elucidate
the relationship of fatty acids and PON1.
Methods
Ethics statement
Institutional review boards at the University of Washington,
Virginia Mason Medical Center, and Veterans Affairs Puget
Sound approved the CLEAR study. Written, informed con-
sent was obtained from each participant of the study.
Sample
The study population for this analysis consisted of 1,548
participants from the previously described CLEAR study
[27,28]. The cohort consisted of 380 participants with
CAAD as determined by ultrasound (>50% stenosis in
either carotid artery), 73 participants with moderate ob-
struction (15-49% obstruction in at least one carotid ar-
tery), 96 subjects with other phenotypes, including
peripheral artery disease (PAD) and coronary artery dis-
ease (CHD), and 999 controls (<15% carotid stenosis bi-
laterally and absence of PAD and CHD). Current
smoking status and reported ancestry were obtained by
self-report. Insulin use was determined via self-report
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included familial hypercholesterolemia, total fasting
cholesterol greater than 400 mg/dl, hypocoagulable state
and/or the use of anticoagulant medication, post-organ
transplant, or the inability to consent. Descriptive statis-
tics of the studied subset of the CLEAR study are pre-
sented in Table 1.
PON1 genotyping and phenotyping
The four PON1 polymorphisms with the largest effects
on PON1 enzyme activity, PON1C-108T, PON1G-162A,
PON1M55L, and PON1Q192R, were genotyped using previ-
ously described methods [8,9]. PON1 activity was measured
by the rate of enzymatic degradation of phenylacetate
(AREase) via a continuous spectrophotometric assay with
lithium heparin plasma, as AREase is least affected by the
PON1Q192R polymorphism and also is more closely related
to PON1 protein levels [6,7]. PON1 AREase activity was
measured in triplicate and averaged for analysis. Measure-
ments were made blinded to phenotype and diet data.
Food-frequency questionnaire
At enrollment, participants were asked to complete the
standardized Harvard food frequency questionnaireTable 1 Baseline characteristics of the studied subset of
the CLEAR cohort
Baseline characteristics CLEAR cohort
(N = 1548)
Ethnicity, n (%)
European ancestry, not Hispanic 1240 (80.1)
Hispanic ancestry 36 (2.3)
African ancestry 128 (8.3)




Age, mean ± SD, years 64.84 ± 9.69
Current smoker, n (%) 179 (11.6)
Dietary fat intake
Saturated fats
ln(Myristic acid (14:0) intake), mean ± SD, g/day 1.03 ± 0.339
Monounsaturated fats
ln(Oleic acid (18:1) intake), mean ± SD, g/day 3.14 ± 0.419
ln(Gadoleic acid (20:1) intake), mean ± SD, g/day 0.242 ± 0.143
Polyunsaturated fats
ln(α-Linolenic acid (18:3) intake), mean ± SD, g/day 0.795 ± 0.239
ln(Arachidonic acid (20:4) intake), mean ± SD, g/day 0.140 ± 0.0666
ln(Eicosapentaenoic acid (20:5) intake), mean± SD, g/day 0.138 ± 0.123
PON1 AREase activity, mean ± SD, IU 149.58 ± 50.47developed by the Health Professionals Follow-Up Study
(https://regepi.bwh.harvard.edu/health/nutrition.html). The
survey asked participants for their average frequency of in-
take of specified portions of 131 foods, vitamins, and min-
eral supplements. The surveys were then returned to
Harvard School of Public Health and the Brigham and
Women’s Hospital, where they underwent quantitative ana-
lysis to return the inferred average intake of all micronutri-
ents, including DFAs, vitamins, and minerals. The Harvard
Food Frequency Questionnaire has been validated against
two, in-depth, 1-week diet records taken approximately six
months apart [29]. Additionally, the inferred intake of diet-
ary fats have been validated against plasma lipid measure-
ments [30,31].
DFA selection
To reduce the number of statistical tests, only DFAs not
highly correlated (r < 0.8) with other DFAs or that were rep-
resentative of other DFAs through high correlation within
each fatty acid group (saturated, monounsaturated, and
polyunsaturated) were carried forward to statistical testing,
as presented in Figure 1. Linear correlation within each
fatty acid group was assessed by Pearson’s correlation coef-
ficient (r). Of the 8 saturated DFAs measured by the food
frequency questionnaire, all were highly correlated with
myristic acid, composed of 14 carbons and no double
bonds (14:0). Within the monounsaturated (fatty acids with
one double bond) fatty acid group, palmitoleic (16:1) and
oleic acid (18:1) were highly correlated with each other,
while the third member, gadoleic acid (20:1) was not
strongly correlated with either. Due to prior reports in the
literature of a positive association between oleic acid and
PON1 activity [19,20,24], oleic and gadoleic acid were car-
ried forward to statistical testing. Within the polyunsatur-
ated fat group, there were 3 clusters of correlation (see
Figure 1). From these correlation blocks, α-linolenic acid
(18:3, a ω-3 DFA), arachidonic acid (20:4, a ω-6 DFA), and
eicosapentaenoic acid (20:5, a ω-3 DFA) moved on to the
stepwise linear regression procedure.
Statistical methods
Natural log transformation was performed for each of the 6
specific DFA intake variables, as they all displayed a skewed
distribution. Extreme observations were Winsorized to 3
standard deviations from the mean [32]. For food frequency
data, participants were excluded if their caloric intake was
<800 calories/day or >4000 calories/day. Additionally, par-
ticipants were excluded if the returned survey had ≥70
missing items.
All analyses were performed in R (http://www.r-pro-
ject.org/). Genotypes were coded using an additive
model. Stepwise linear regression was performed with
the 6 specific DFA intake variables entering the model.
Model comparison was performed using Akaike’s
Figure 1 Selection of specific dietary fatty acid intakes for analysis by correlation. Correlation matrix between specific dietary fatty acids
within the group of saturated (a), monounsaturated (b), and polyunsaturated fatty acids (c). To reduce the number of statistical tests, only those
dietary fatty acids not highly correlated (Pearson’s pairwise correlation coefficient, r, < 0.8) with others in its group were carried forward to
analysis. If numerous fatty acid intakes were highly correlated (r≥ 0.8), a single representative was chosen.
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model that included age, sex, current smoking status,
self-reported race (with European ancestry as the refer-
ence group, as they comprised the majority of the co-
hort), and the genotypes of the 4 functional PON1
polymorphisms as covariates for the prediction of PON1
AREase activity. Only specific DFA intakes that im-
proved model prediction of the outcome PON1 AREase
activity were retained in the final model. To identify
whether DFAs account for variance previously explained
by dietary cholesterol or other variables, a secondary
analysis in the previously published subset of the cohort
(n = 1402 participants) was performed; in addition to the
effects of dietary cholesterol, vitamin C, folate, iron, and
insulin use on PON1 activity that had previously been
reported to be significant in this subset [18].
Results
Demographic, clinical, and dietary fat intake variables
are presented in Table 1. Participants of self-reported
European, non-Hispanic ancestry composed the majority
of the cohort (80.1%). Subjects of Asian (9.3%), African
(8.3%), and Hispanic (2.3%) ancestry composed the re-
mainder of the cohort. Males accounted for approxi-
mately two-thirds (64.9%) of the studied population. The
average age of all subjects was 64.8 years, and 11.6% of
the cohort were current smokers. PON1 AREase activity
had a mean of 149.6 IU with a standard deviation of
50.5 forming an approximate normal distribution.
To reduce the number of statistical tests performed
and problems with colinearity, only 6 of the 17 available
DFA intakes were selected for stepwise linear regression.The 6 selected DFAs were highly correlated with other
DFAs in each group (saturated, monounsaturated, poly-
unsaturated) and therefore captured the majority of the
group variation while minimizing the problems that arise
with colinearity. The 6 selected DFAs were: myristic acid
(14:0, saturated fat), oleic acid (18:1, monounsaturated fat),
gadoleic acid (20:1, monounsaturated fat), α-linolenic acid
(18:3, polyunsaturated ω-3 fat), arachidonic acid (20:4, poly-
unsaturated ω-6 fat), and eicosapentaenoic acid (20:5, poly-
unsaturated ω-3 fat). The correlation between the selected
DFAs and the other DFAs in each group are summarized
in Figure 1.
A baseline regression model containing the 4 functional
PON1 variants (PON1C-108T, PON1G-162A, PON1M55L, and
PON1Q192R), age, sex, current smoking status, and genetic
ancestry explained 25.1% of PON1 AREase variance. We
then examined a best-fit model using stepwise linear regres-
sion with the base model and the 6 DFAs identified through
correlation testing. Only those DFAs that improved model
prediction through assessment by AIC were retained in the
final, best-fit regression model.
In the best-fit regression model, 4 of the 6 DFA intakes
were retained in addition to the base model, together
explaining 26.3% of PON1 AREase activity (see Table 2).
The 4 specific DFAs (myristic acid (p = 0.038), gadoleic
acid (p = 6.68 × 10-7), arachidonic acid (p = 0.00069), and
eicosapentaenoic acid (p = 0.0134)) serially explained
0.25%, 0.58%, 0.61%, and 0.29% of PON1 AREase activ-
ity, respectively. Myristic acid (beta coefficient = 7.71), a
saturated fat, and gadoleic acid (beta coefficient = 59.50),
a monounsaturated fat, were both significantly positively
associated with an increase in PON1 AREase activity.
Table 2 Best-fit model from stepwise linear regression predicting PON1 AREase activity using dietary fat intake
variables (n = 1548 subjects)
Variablea,b Estimate ± SE % PON1 AREase variation P
(Intercept) 236.85 ± 9.57 - < 2 × 10-16
PON1C-108T −26.48 ± 1.94 13.30% < 2 × 10
-16
PON1G-162A −1.31 ± 2.24 0.21% 0.56
PON1Q192R −12.34 ± 2.08 2.38% 3.83 × 10
-9
PON1M55L −6.16 ± 2.16 0.42% 0.0044
Age −0.94 ± 0.12 2.81% 5.54 × 10-15
Sex 17.95 ± 2.42 4.70% 2.17 × 10-13
Current smoker −13.43 ± 3.58 0.44% 0.00018
Hispanic ancestryc 2.43 ± 7.40 0.01% 0.74
African ancestryc −17.04 ± 4.52 0.71% 0.00017
Asian ancestryc −5.55 ± 4.278 0.13% 0.19
ln(Myristic acid (14:0) intake) 7.71 ± 3.71 0.25% 0.038
ln(Gadoleic acid (20:1) intake) 59.50 ± 11.92 0.58% 6.68 × 10-7
ln(Arachidonic acid (20:4) intake) −67.15 ± 19.76 0.61% 0.00069
ln(Eicosapentaenoic acid (20:5) intake) −33.01 ± 13.33 0.29% 0.013
aln(Oleic acid (18:1) intake) was not significantly associated with PON1 AREase activity (p = 0.246, beta coefficient = 3.52) and was not retained in the final stepwise
regression model.
bln(α-Linolenic acid (18:3) intake) was not significantly associated with PON1 AREase activity (p = 0.913, beta coefficient = −0.579) and was not retained in the final
stepwise regression model.
cGenetic ancestry coded as dummy variable, with European ancestry (the majority of the CLEAR cohort) subset used as the reference group.
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fats, arachidonic acid (beta coefficient = −67.15) and ei-
cosapentaenoic acid (beta coefficient = −33.01), were
both significantly negatively associated with PON1
AREase activity. Sensitivity analyses stratifying by sex
and CAAD status did not reveal significant differences
in subgroup coefficient sizes or p-values, suggesting that
these factors were not affecting the relationship between
specific DFA intake and PON1 enzyme activity.
To determine whether the PON1 activity–DFA associ-
ation was related to the prior report of an association
with dietary cholesterol in this cohort, we performed a
secondary analysis in the previously published subset of
the cohort (n = 1402 participants), in which an associ-
ation between dietary factors including cholesterol and
PON1 activity was detected [5,18]. Gadoleic (r = 0.33),
myristic (r = 0.64) and arachidonic acid (r = 0.82) were
significantly correlated (p < 0.001) with dietary choles-
terol intake, while eicosapentaenoic acid (r = 0.16) was
not.
In the best-fit model, 36.5% of PON1 AREase activity was
explained, as opposed to 35.04% when DFAs were not in-
cluded in the model (see Table 3 for specific model coeffi-
cients and p-values and Figure 2 for a summary of PON1
AREase activity explained). All 6 previously reported dietary
and clinical variables that affected PON1 AREase activity
(dietary cholesterol, vitamin C, folate, iron, alcohol intake,
and insulin use) were retained in the final model in addition
to the 4 specific DFA intakes. Addition of dietary DFA tothe model reduced the coefficient of the dietary cholesterol
effect by approximately 10% (from 59.70 to 56.41) and the
variance explained by dietary cholesterol from 5.45 to
4.98%. Similarly, the effect sizes of gadoleic (from 59.50 to
46.78) and arachidonic acid (from −67.15 to −34.17) de-
creased by 21.4% and 49.1%, respectively, with dietary chol-
esterol intake in the model. However, DFAs accounted for
1.2% of PON1 activity variance; thus, the total variance ex-
plained by dietary cholesterol and DFAs was greater than
for dietary cholesterol alone.
Discussion
PON1 is an HDL-associated enzyme that is involved in
numerous human disease-related pathways. PON1 is
atheroprotective [4,33], an antioxidant [34,35], can help
to decrease the lethality of Pseudomonas aeruginosa in-
fections [36,37], and it hydrolyzes numerous compounds
– including pharmacologic agents [3,17,38] and toxic or-
ganophosphorus compounds [39,40]. A full understand-
ing of PON1 should include the dietary factors that
affect its expression and activity [18,26].
In the current study, we analyzed what we believe to
be the largest cohort with both dietary intake and PON1
enzyme activity data, and report that the monounsatu-
rated DFA, gadoleic acid (20:1), is strongly associated
with an increase in PON1 activity. We also observed a
strong decrease in PON1 enzyme activity associated with
increasing polyunsaturated fat intake of arachidonic
(20:4) and eicosaepentaenoic (20:5) acid. Finally, we
Table 3 Best-fit model from stepwise linear regression predicting PON1 AREase activity using both dietary fat and
other intake variables (n = 1402 subjects)
Variable Estimate ± SE % PON1 AREase variation P
(Intercept) −71.40 ± 35.70 - 0.046
PON1C-108T −27.99 ± 2.13 13.61% <2 × 10
-16
PON1G-162A −2.42 ± 2.40 0.11% 0.31
PON1Q192R −12.73 ± 2.24 1.92% 1.73 × 10
-8
PON1M55L −5.50 ± 2.31 0.54% 0.017
Age −0.808 ± 0.135 3.57% 2.89 × 10-9
Sex 16.88 ± 2.77 5.45% 1.49 × 10-9
Current smoker −15.34 ± 3.88 0.70% 8.24 × 10-5
Hispanic ancestry 6.06 ± 8.27 0.001% 0.46
African ancestry −12.99 ± 5.02 0.58% 0.0097
Asian ancestry −5.44 ± 5.29 0.015% 0.30?
Insulin use −13.07 ± 5.76 1.02% 0.023
ln(Dietary cholesterol)a,b,c 53.41 ± 6.22 4.98% <2 × 10-16
Alcohol category 6.27 ± 1.17 1.84% 1.11 × 10-7
ln(Vitamin C) 4.73 ± 1.51 0.23% 0.0018
Iron −0.219 ± 0.0794 0.54% 0.0057
Folate −0.00904 ± 0.00466 0.19% 0.053
ln(Myristic acid (14:0) intake)a 8.95 ± 4.05 0.41% 0.027
ln(Gadoleic acid (20:1) intake)b 46.78 ± 12.60 0.27% 0.00021
ln(Arachidonic acid (20:4) intake)c −34.17 ± 21.56 0.15% 0.11
ln(Eicosapentaenoic acid (20:5) intake) −36.96 ± 14.24 0.36% 0.0096
aln(Dietary cholesterol) was significantly correlated (p < 0.001) with ln(Myristic acid) (r = 0.64).
bln(Dietary cholesterol) was significantly correlated (p < 0.001) with ln(Gadoleic acid) (r = 0.33).
cln(Dietary cholesterol) was significantly correlated (p < 0.001) with ln(Arachidonic acid) (r = 0.82).
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of the saturated fat, myristic acid (14:0), on PON1
AREase activity. “We note that when considering previ-
ously reported dietary variables, the addition of DFA in-
take explained an additional 1.2% of PON1 AREase
activity. Although 1.2% of PON1 activity may seem mod-
est, it compares well to the scale of effects found for
complex traits, including lipids [41]. Moreover, this data
may reveal a new biological avenue for investigation re-
garding the potential regulation of PON1 by the dietary
intake of fatty acids; namely, whether the mechanism
through which DFAs intake affects PON1 activity is
through gene regulation, direct protein interaction, or
other more indirect processes. Finally, due to the ubiqui-
tous nature of PON1 in human disease and physiology
[17], understanding even a small portion of its variance
is of high importance.
Monounsaturated fats have been previously positively as-
sociated with PON1 activity in human [20,21] and animal
[19] studies. Evidence from in vitro studies suggests that
both saturated and monounsaturated fats bind to a specific
and protective site, separate from the catalytic active site, to
prevent inactivation of PON1 through oxidation [24,25].Moreover, in vitro evidence suggests that this binding of
saturated and monounsaturated fats decreases PON1 activ-
ity only marginally (approximately 10%) [24]. The strongly
protective effects of monounsaturated DFAs are broad: pro-
tection of PON1 from oxidation was not dependent on ei-
ther carbon chain length or location of the double bond
[24]. In our specific study, we did not find a strong associ-
ation between oleic acid (the most commonly reported
monounsaturated fat) and PON1 activity; when gadoleic
acid was removed from the best-fit regression model, oleic
acid was not significantly associated with PON1 activity
(see Table 2). We did, however, find a strongly positive asso-
ciation of gadoleic acid (beta coefficient = 59.50, p = 6.68 ×
10-7) on PON1 activity. The exact molecular mechanism
for our finding, though suggested, is yet unknown, as are
possible other mechanisms, including potential effects on
PON1 expression.
While the ω-3 and ω-6 DFAs commonly found in fish
oil are generally thought to be cardioprotective [42],
prior research has found fish oils, and the polyunsatur-
ated fatty acids that compose fish oil, to be inhibitory to
PON1 activity [19,23,24]. In vitro work suggests that
polyunsaturated DFAs are recognized by the active site
Figure 2 Percentage of PON1 AREase activity explained by the dietary covariates considered. Refer to Table 3 for complete stepwise
model information.
Kim et al. Lipids in Health and Disease 2013, 12:183 Page 7 of 9
http://www.lipidworld.com/content/12/1/183of PON1 and therefore act as competitive inhibitors of
PON1 enzyme activity [24]. Moreover, binding of poly-
unsaturated fats appears to change the conformation of
the protein, preventing protective binding of monoun-
saturated and saturated DFAs and, therefore, increasing
the susceptibility of PON1 to inactivation from oxidation
[24]. Consistent with prior report, we found that 2 (ara-
chidonic and eicosaepentaenoic acid) of the 3 tested
polyunsaturated DFAs were negatively associated with
PON1 activity. The third polyunsaturated fatty acid, α-
linolenic acid, trended negative, but was not significantly
associated with PON1 activity (see Table 2). Thus, the
cardioprotective effects of fish oil and polyunsaturated
fats appear to occur in spite of what appear to be inhibi-
tory effects on PON1 enzyme activity, whose activity is
associated with atheroprotection.
When considering dietary intakes that we previously have
reported [18], we were able to explain a total of 36.5% of
PON1 AREase activity. However, we note that with the
addition of these dietary covariates, there was a decrease in
the magnitude of the beta coefficients and percentage of
PON1 activity explained for both gadoleic acid and arachi-
donic acid. This likely is due to the highly significant correl-
ation between both gadoleic (r = 0.33) and arachidonic
(r = 0.82) acid with dietary cholesterol intake. Dietary chol-
esterol intake was the third most predictive covariate (after
PON1C-108T and gender) and accounted for approximately5% of PON1 AREase activity. However, after accounting for
the effects of dietary cholesterol intake, both gadoleic and
arachidonic acid were retained in the best-fit stepwise re-
gression model. This indicates that both DFAs have effects
on PON1 activity that are independent of the large effects
of dietary cholesterol intake and which aid in the prediction
of PON1 AREase variance.
Strengths of this study include its large, well-
characterized community-based cohort with dietary in-
take information, genetic data, and lipid phenotypes. To
the best of the authors’ knowledge, this is the largest
analysis of the effects of DFAs on PON1 activity. Limita-
tions include the lack of ethnic diversity and that the
cohort was collected primarily for CAAD, with partici-
pants that tended to be older than the general popula-
tion. Together, these limitations may limit the
generalizations and applications of these findings. Fi-
nally, the food frequency questionnaire used had limited
data on several dietary covariates of interest: namely,
trans fats, which have previously been reported to be in-
hibitory to PON1 activity [22]. As a result, some DFA
associations with PON1 could not be assessed in this
analysis.
In conclusion, our study has identified and confirmed
the effects of specific fatty acid intakes on PON1 activity
in a large cohort collected for vascular disease. Specific-
ally, we report the positive association of saturated fats
Kim et al. Lipids in Health and Disease 2013, 12:183 Page 8 of 9
http://www.lipidworld.com/content/12/1/183(myristic acid, p = 0.038) and monounsaturated fats
(gadoleic acid, p = 6.68 × 10-7) on PON1 AREase activity
and the PON1 activity decreasing effects of the polyun-
saturated fats, arachidonic (p = 0.00069) and eicosa-
pentaenoic (p = 0.013) acid. When considered in
conjunction with our previously reported dietary, gen-
etic, and clinical covariates [18], we were able to explain
36.5% of PON1 AREase activity. Further work character-
izing the 63.5% unexplained PON1 variance should con-
sider the possible effects of rare PON1 variation [14,15],
epistasis of PON1 with other genes, and gene-by-
environment interactions [43] in the attempts to further
understand the determinants of this important and
multi-faceted enzyme.
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